Features & Analyses

GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale

GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale

After five years, MOFCOM has updated its merger control notification rules. Although big improvements have been made, issues with determining control and new joint venture turnovers still need clarification

After five years, MOFCOM has updated its merger control notification rules. Although big improvements have been made, issues with determining control and new joint venture turnovers still need clarification

Many foreign companies are being attacked by Chinese companies for payment under guarantee fraud claims. Peng Shen and Ying Wu explain how devising a comprehensive dispute resolution strategy is key to avoid and manage these risks

SAFE has relaxed its control over foreign exchange for cross-border security. Yun Chen believes the new rules are an important breakthrough for onshore and offshore financing

Sherman Chu, general counsel for Cisco, shares with China Law & Practice his thoughts on the developing competition regime in China and where the AML is headed

The new NDRC Measures have made Chinese outbound investments easier by raising requirement thresholds and simplifying the approval process. This could reduce the premium often demanded by foreign sellers and boost the domestic economy

The new NDRC Measures have made Chinese outbound investments easier by raising requirement thresholds and simplifying the approval process. This could reduce the premium often demanded by foreign sellers and boost the domestic economy